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The role of heparan sulfate in the 
glomerular basement membrane
H Morita1, A Yoshimura1 and K Kimata2
Recent studies, including those by van den Hoven and colleagues, 
have challenged the classic negative-charge theory of glomerular 
filtration. However, the possibility remains that heparan sulfate in 
the glomerular basement membrane plays a role in maintaining the 
glomerular filtration barrier.
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In the glomerulus, transport of circulating 
albumin into the urinary space is strictly 
regulated by a ﬁltration barrier that con-
sists of size- and charge-selective ﬁlters. For 
decades, the issue of which component of 
the glomerulus constitutes the ﬁltration 
barrier has been a subject of investigation 
by nephrologists. Ultrastructural stud-
ies with cationic/neutral/anionic tracers 
performed in the 1960s, 1970s, and 1980s 
led us to believe ﬁrmly that the glomerular 
basement membrane (GBM) functions 
as the ﬁltration barrier;1 that circulating 
albumin is repelled by the negative charge 
of the GBM; that heparan sulfate (HS) car-
ries the negative charge in the GBM; and 
that loss of HS in the GBM results in mas-
sive proteinuria. Some investigators in the 
mid-1990s questioned the interpretation of 
earlier tracer studies.2 The ‘negative-charge 
theory’ described above was favored until 
the slit diaphragm molecule nephrin was 
discovered in 1998.3 Subsequent studies of 
rare human families and genetically altered 
animals led to the identiﬁcation of other slit 
diaphragm molecules that play important 
roles in glomerular ﬁltration. Some of these 
molecules interact with signaling mol-
ecules that regulate the actin cytoskeleton 
of podocyte foot processes. Attention 
shifted from the GBM to podocytes, not 
because the negative-charge theory was 
disproved, but because podocytes became 
so attractive. Although knowledge regard-
ing the function of podocytes has increased 
vastly in the past decade, it is time for us to 
revisit the negative-charge theory. Molecu-
lar techniques are now available to exam-
ine decisive questions; recent studies have 
suggested that the glomerular ﬁltration 
barrier is complex. The following funda-
mental questions can now be addressed: 
(1) does the GBM function as a ﬁltration 
barrier? and (2) is HS in the GBM essential 
for maintaining the barrier?
With respect to the first question, no 
one doubts the importance of podocytes 
in maintaining the ﬁltration barrier. How-
ever, the fact that podocytes are impor-
tant does not exclude a role of the GBM. 
Laminin β2-chain, which is encoded by 
the LAMB2 gene, is an essential constitu-
ent of the GBM. In 1963, Pierson reported 
that two sisters with congenital nephrotic 
syndrome progressed to end-stage renal 
disease and microcoria. Forty years later, 
LAMB2 mutations were found in patients 
from ﬁve unrelated families that showed 
clinical manifestations similar to those 
described by Pierson.4 LAMB2 mutations 
were found in 2.5% of patients in a Euro-
pean cohort of 89 children from 80 families 
with nephritic syndrome, which appeared 
within the ﬁrst year of life. In Lamb2–/– 
mice, anionic sites in the GBM were disor-
ganized.5 Albuminuria preceded podocyte 
foot process eﬀacement, which was visible 
about 2 weeks after birth. Ferritin perme-
ability of the GBM was markedly increased 
in Lamb2–/– mice, but not in nephrotic 
Cd2ap–/– mice, which showed a primary 
podocyte defect and no alterations in the 
distribution of anionic sites in the GBM. 
These ﬁndings indicate that the GBM and 
the slit membrane act as ﬁltration barriers.
To address the question of whether 
HS in the GBM is necessary to maintain 
the filtration barrier, we must first dis-
cuss the biochemical features of HS. HS 
is a polysaccharide classiﬁed as a form of 
glycosaminoglycan, a polysaccharide that 
contains amino sugars (glycosamines). 
The basic glycosaminoglycan structure is 
a simple repeat of two sugar (disaccharide) 
units. In the case of HS, D-gluconate (GlcA) 
and N-acetyl-D-glucosamine (GlcNAc) 
units joined in 1→4 linkages are repeated 
(Figure 1). However, a variety of chemical 
modiﬁcations can be introduced, resulting 
in enormous structural complexity. HS is 
subject to several modiﬁcations, includ-
ing conversion of D-GlcA to L-iduronate 
(IdoA) through C5-epimerization, forma-
tion of N-sulfated GlcN (GlcNSO3) units 
through N-deacetylation/N-sulfation, and 
formation of O-sulfated (-OSO3) GlcA, 
IdoA, or GlcNAc through O-sulfation at 
positions 2, 3, and 6. For example, 2-O-sul-
fated IdoA (O-sulfated IdoA at position 2, 
or IdoA[2-OSO3]), 6-O-sulfated GlcNAc 
(O-sulfated GlcNAc at position 6, or Glc-
NAc[6-OSO3]), and 6-O-sulated GlcNSO3 
(O-sulfated GlcNSO3 at position 6, or Glc-
NSO3[6-OSO3]) are major constituents 
of HS (Figure 1). The large numbers of 
N- and O-sulfation in this macromolecule 
yield very strong anionic charges. In fact, 
the negative-charge densities of heparin 
and HS, which have very similar molecular 
structures, are stronger than those of any 
other macromolecules in vivo. HS is sug-
gested to be the molecular source of the 
negative charges in the GBM.
Van den Hoven and colleagues6 (this 
issue) now describe the kidney phenotypes 
of mice overexpressing human heparanase 
(HPSE-tg), which has been a useful tool in 
studies of the nature of HS in the GBM. 
They prepared a large panel of anti-HS 
monoclonal antibodies to show not only 
that diﬀerent HS epitopes are present in the 
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GBM but also that some of the HS epitopes 
differ from those in tubular basement 
membranes or the basement membranes 
of Bowman’s capsule. These results are in 
agreement with the concept that tissue- 
and function-specific expression of HS 
structures exists as originally suggested 
by basic carbohydrate researchers. The 
immunohistochemical data from van den 
Hoven and colleagues6 clearly show that 
some HS epitopes in the GBM are lost in 
HPSE-tg mice. Their ultrastructural analy-
sis with a cationic dye indicates that anionic 
sites were reduced in the GBM of HPSE-tg 
mice. Morphology of the glomerulus was 
unchanged, and massive proteinuria was 
not observed.
Two groups of HS-degrading enzymes 
are known. One is bacterial heparan sul-
fate lyase, a heparitinase that catalyzes the 
eliminative cleavage of the α-N-acetyl-D-
glucosaminidic linkage in HS. The other 
is bacterial or mammalian endoglucuro-
nidase, a heparanase that catalyzes the 
hydrolytic cleavage of glycosidic bonds 
in HS. Mammalian cells express a single 
major heparanase. In humans, the gene 
HPSE-1 maps to 4q21.3, contains 14 
exons, and encodes a 65-kilodalton pre-
cursor protein. Proteolysis yields active 
heparanase, a heterodimer of 50- and 
8-kilodalton proteins. Substrate spe-
cificity of mammalian heparanase was 
investigated on a biochemical basis. 
HexUA(2S)-GlcN(NS,6S)-IdoA-
GlcNAc(6S)-GlcA-GlcN(NS,+/–6S)-
IdoA(2S)GlcN(NS,6S) may be a candidate 
physiologic target octasaccharide sequence 
for human heparanase.7 In van den Hoven 
and colleagues’ work,6 HS epitopes recog-
nized by the NAH46 and AO4B08 antibod-
ies were resistant to heparanase digestion. 
The authors deduced from cationic dye 
staining that approximately 20% of the 
GBM HS was resistant to heparanase diges-
tion in HPSE-tg mice. However, biochemi-
cal analysis of the GBM HS is necessary to 
determine whether this value is underesti-
mated, although such an analysis is techni-
cally diﬃcult to achieve.
In ﬁndings similar to those of van den 
Hoven et al.,6 a recent study published 
in the Journal of the American Society of 
Nephrology showed that removal of GBM 
HS in rats by injection of HS-degrading 
enzyme did not lead to proteinuria.8 In 
spite of this line of evidence, it is too early 
for us to conclude that GBM HS does not 
play an important role in maintaining ﬁl-
tration barrier. Van den Hoven and col-
leagues state that one cannot exclude the 
role of loss of GBM HS in the development 
of proteinuria. They hypothesize that 
development of proteinuria in human 
glomerulonephritis may be mediated by 
a multi-hit or multi-signal mechanism 
that consists of loss of GBM HS, release of 
various growth factors/cytokines bound to 
HS, and unfavorable activation of podo-
cytes.9 Experimental manipulation of only 
one signal may not be suﬃcient to mimic 
the condition present in glomerulonephri-
tis with proteinuria in humans. Further-
more, there is evidence that expression of 
glomerular heparanase is increased in a 
variety of proteinuric disorders in mice, 
rats, and even humans.9,10 Structure- 
oriented studies of HS might be unfamil-
iar, but they deepen our understanding 
of the roles of HS in the GBM and may 
facilitate generation of new HS-based 
drugs to treat proteinuria. In the light of 
recent ﬁndings, the classic negative-charge 
theory may need some modification. 
However, the possibility remains that HS 
in the GBM plays a role in maintaining 
the glomerular ﬁltration barrier.
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Figure 1 | Heparan sulfate (HS) in the glomerular basement membrane (GBM). HS is covalently 
bound to a serine residue of a proteoglycan core protein via a tetrasaccharide linkage region 
(sawtooth line). The polysaccharide of HS is a simple repeat of D-glucuronate and N-acetyl- (or 
sulfo-)D-glucosamine joined by 1→4 linkages. The combination of X, Y, and Z as well as ‘n’  in 
the figure varies. Furthermore, the conversion of D-glucuronate (asterisk) to L-iduronate by C5-
epimerization and 3-O-sulfation of D-glucosamine (double asterisk) can occur.
